RPX2014 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses RPX2014 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses RPX2014 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult SubjectsCompletedPhase 1Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)NCT02073812Written as RPX7009 and RPX2014
- The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal InsufficiencyCompletedPhase 1Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)NCT02020434Written as RPX7009 and RPX2014
- Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult SubjectsCompletedPhase 1Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)NCT01897779Written as RPX2014